Benzinga | Nov 15, 2021 10:46AM EST

Goldman Sachs Downgrades TG Therapeutics to Sell, Lowers Price Target to $26

Goldman Sachs analyst Graig Suvannavejh downgrades TG Therapeutics (NASDAQ:TGTX) from Neutral to Sell and lowers the price target from $33 to $26.